Therapeutic Approach

Archive: April, 2017

Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities

Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”) today, April 12, 2017, announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017. The Company plans to discuss the results of its recently […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD